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Background: Neuropathic pain can reduce the quality of life and independence of 30% to 50% of patients with
diabetes. The comparative effectiveness of analgesics for patients with diabetic neuropathy remains unclear. The
aim of the current work, therefore, was to summarize the evidence about the analgesic effectiveness of the most
common oral and topical agents used for the treatment of peripheral diabetic neuropathy.
Methods: We will use an umbrella approach (systematic review of systematic reviews) to identify eligible randomized
controlled trials (RCTs) for the most common oral or topical analgesics for painful diabetic neuropathy. Two reviewers
will independently determine RCT eligibility. Disagreement will be solved by consensus and arbitrated by a third
reviewer. We will extract descriptive, methodological and efficacy data in duplicate. Results will be pooled and analyzed
using classic random-effects meta-analyses and network meta-analyses to compute the absolute and relative efficacy
of therapeutic options. We will use the I2 statistic and Cochran’s Q test to assess heterogeneity. Risk of bias and
publication bias, if appropriate, will be evaluated, as well as overall strength of the evidence.
Discussion: This network meta-analysis aims to synthesize available direct and indirect evidence of effectiveness of
analgesics in the treatment of painful diabetic neuropathy. The network approach will offer the opportunity to
generate a ranking based on efficacy and along with known side effects, costs, and administration burdens will enable
patients and clinicians to make choices that best reflect their preferences for treatment of painful diabetic neuropathy.
Keywords: Comparative effectiveness research, Diabetic neuropathy, Network meta-analysis, Systematic reviewBackground
Diabetic neuropathy is the most common complication
of diabetes. It usually has a distal symmetric pattern that
slowly progresses proximally with major implications to
quality of life. It affects the function, mood and sleep
patterns of the majority of affected patients. Symptoms
include neuropathic pain, burning, tingling, decreased
sensation, and loss of temperature perception [1-4].
Neuropathic pain is present in 30% to 50% of patients
with diabetes [5,6].* Correspondence: Griebeler.marcio@mayo.edu
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reproduction in any medium, provided the orGlycemic control has been shown to be effective in slow-
ing the progression of diabetic neuropathy [7]. Patients
with painful neuropathy often need other agents to palliate
their symptoms. Agents used include tricyclic antidepres-
sants, anticonvulsants, serotonin-norepinephrine reuptake
inhibitors, opiates, opiate-like substances and topical medi-
cations. However, these medications usually at best provide
only partial pain relief [2,5,6].
There is no clear evidence-based guidance about treat-
ment selection of analgesic agents for painful diabetic
neuropathy. Stepwise approach and algorithms may be
used, but comparative effectiveness of treatments to
control pain in patients with diabetic neuropathy isal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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across the different drug classes or the individual agents.
We therefore decided to conduct a systematic review to
appraise and summarize the totality of evidence regarding
the efficacy of the most common non-parenteral (oral and




Considering the large number of pharmacologic therap-
ies and the availability of multiple systematic reviews
that identified the efficacy trials of these drugs, we
decided to follow an ‘umbrella’ [8,9] approach to identify
eligible randomized controlled trials (RCTs). In brief, we
will identify systematic reviews that compare available
therapeutic options for painful diabetic neuropathy to
placebo or any other active comparators. Eligible system-
atic reviews will be retrieved and used to identify
relevant RCTs. We will subsequently build a dataset
comprising eligible RCTs to obtain, critically appraise for
quality, and extract data from each RCT to be used for
the meta-analyses of relevant outcomes. Extracted data
will be combined using a network design to draw infer-
ences about the absolute and relative efficacy (from dir-




Two study investigators with expertise in diabetes (VMM
and AT) provided input about the most common drugs
used for diabetic neuropathy in USA and Europe. A list
describing the most commonly used therapies deemed eli-
gible for this review, with their minimum effective dose
and therapeutic range based on American Diabetes Asso-
ciation (ADA) recommendations or expert opinion is pre-
sented in Table 1. For a trial to be included, the
intervention dose evaluated must be at least the minimum
effective dose cited in Table 1. This was set to reduce the
risk of bias when an agent is compared to an ineffective
dose of a competitor. If more than one dose is evaluated
within the same RCT, we will include the results of
patients treated with the highest dose in the efficacy com-
parisons, again ensuring that this dose is within the usual
or recommended use of the agent.
Study design
During the umbrella stage of this systematic review, we
will perform a literature search for all systematic reviews
(any review with a clear and relevant clinical question, an
explicit strategy and list of results) summarizing evidence
from randomized trials testing treatments for painful
diabetic neuropathy or neuralgia (Additional file 1).From these reviews, we will identify eligible trials.
These should enroll patients with painful distal symmet-
rical polyneuropathy and randomly allocate these
patients to treatment and control while keeping patients
unaware of the therapy to which they have been allo-
cated. There will be no restriction based on language of
publication, number of patients or type of diabetes.
Figure 2 illustrates the process of study selection.
Information sources and search methods
We will conduct a comprehensive literature search for
systematic reviews published in the last 5 years (2007 to
2011) for diabetic neuropathy or neuralgia in major elec-
tronic databases (MEDLINE™ via Ovid, EMBASE via
Ovid, and the Cochrane Database of Systematic Reviews).
Two study investigators with experience in systematic
reviews (VMM and MHM) and an expert reference librar-
ian developed the search strategy (Additional file 1) using
a combination of controlled vocabulary (MeSH terms)
and key words for the concepts of treatment of neuralgia
or diabetic neuropathy.
Two reviewers working independently will identify by
title and abstract screening systematic reviews for the
treatment of diabetic neuropathy. We will retrieve system-
atic reviews and meta-analyses deemed to be relevant and
review them in full text to extract all eligible RCTs. These
will be retrieved in full text for further assessment.
Two reviewers will independently determine RCT eli-
gibility. Disagreement will be solved by consensus, or if
consensus is not achieved a third reviewer will serve as
an arbitrator. We will assess chance-adjusted agreement
(κ statistic) for each step. We will extract descriptive,
methodological and analgesic efficacy data in duplicate.
Outcomes
The main outcome of this study is improvement of pain.
We are going to assess this outcome both as a dichotom-
ous (for example, percentage of patients experiencing an
improvement of pain of at least ≥30%) and a continuous
variable (for example, standardized mean difference on a
pain scale). If both dichotomous and continuous outcome
data are available from the same trial, data for each vari-
able will be analyzed separately. If pain is reported both in
upper and lower extremities, we will analyze data only for
the lower extremities. We understand that several out-
comes describing pain may be reported and we have
therefore decided to build a hierarchy of the pain out-
comes we will consider. We will prefer, in decreasing
order of relevance, intensity, overall pain, quality, dur-
ation, and timing. If pain is reported at multiple time
points, we will assess efficacy of treatment at subacute (≤3
months) and chronic timeframes (anything >3 months). If
multiple assessments are reported, we will use the longest
time point within the aforementioned categories.
Figure 1 Example of network of direct comparisons for the multiple-treatments meta-analysis for the outcome of interest that will be
used. The thickness of the connecting lines is proportional to the number of available direct comparisons. The size of each node is proportional
to the number of trials that investigated each treatment. The information in this figure is preliminary and will be updated after the search and
analysis. AC = anticonvulsant; ARI = aldose reductase inhibitor; SSRI = selective serotonin reuptake inhibitor.
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outcomes of interest. We will standardize all scales,
hence creating a unitless metric of pain, by expressing
differences in number of standard deviations (standar-
dized difference), which will allow comparison among
the different scales (Figure 3).
For parallel-arm placebo-controlled trials and com-
parative effectiveness head-to-head trials, differences will
be calculated between arms. Crossover trials are going
to be analyzed according to recommendations from the
Cochrane Handbook for Systematic Reviews of Interven-
tions [8].
The network approach will generate a ranking list
based on efficacy. According to the results we will rank
all the included medications from most to least effective
based on their effect on pain scores.Data collection and extraction
Data from RCTs will be extracted in duplicate, by
independent reviewers, using a standardized, piloted,
web-based data extraction form. We will re-extract data
from each randomized clinical trial on patient demo-
graphics, baseline characteristics (duration of diabetes,
hemoglobin A1c (HbA1c)), study design, sample size,
intervention type (class, type and dosages), scale type,
reporting of functional status outcomes or impaired
sleep pattern.Risk of bias assessment
We will use the Cochrane Collaboration’s risk of bias tool
to evaluate the methodological quality of RCTs. Two
reviewers will independently assess risk of bias using the
following domains: random sequence generation (ad-
equate if based on computer generated random numbers,
tables of random numbers or similar), allocation conceal-
ment (adequate if based on central randomization, sealed
envelopes or similar), blinding of patients care givers or
outcome assessors, incomplete outcome data (due to high
rate of discontinuation, loss to follow-up, type of analysis,
or imputation of missing data), selective reporting and
other bias (source of funding, whether by not-for-profit or
for-profit sources.) Disagreements between reviewers will
be resolved by discussion or will be arbitrated by a third
reviewer (MHM). We will summarize the risk of bias at
all six domains to produce an overall risk of bias for every
trial. This will be deemed high if there is presence of high
bias in any key domain (allocation concealment or blind-
ing of patients), low if risk of bias is low for all key
domains, and unclear in all other cases. We chose a priori
to consider allocation concealment and blinding as key
quality domains, due to their relative importance for as-
sessment of subjective outcomes such as pain, and have
formulated an a priori rule to summarize risk of bias for
every class of outcomes across domains, based on scoring
of risk of bias in every domain of the Cochrane Risk of
Bias tool [8].
Table 1 Most commonly used therapies for treatment of
diabetic neuropathy
Class Medication Minimum effective dose
(total daily dose)














Sodium valproatea 400 mg
Topiramatea 100 mg
















Various Lacosamidea 100 mg
aNo dose recommended by the American Diabetes Association.
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We will use the GRADE (‘Grading of Recommendation,
Assessment, Development and Evaluation’) framework to
evaluate the quality of evidence. Evidence derived from the
RCTs will be initially considered high (at low risk of bias)
and subsequently downgraded based on methodological
limitations, imprecision, inconsistency, indirectness and
publication bias [10]. A final generated grade will reflect
the confidence we have in the reported estimate of effect.
Statistical analysis
We will pool odds ratios (ORs) for pain improvement
reported as a dichotomous outcome and standardizedmean differences (SMDs) using Hedges’ adjusted g for
pain scores based on different scales from included stud-
ies, accompanying 95% confidence intervals (CI). Then,
we will conduct pairwise meta-analyses and estimate the
combined efficacy of treatment using a random effects
model using the method of DerSimonian and Laird, with
the estimate of heterogeneity being taken from the
Mantel-Haenszel model [11]. Network meta-analyses
will be adopted to combine direct and indirect evidence
using Lumley’s generalized linear mixed models based
on Frequentists’ method. The Bayesian Markov Chain
Monte Carlo method will also be used as an alternative
statistical method to validate the results.
Generalized linear mixed models
We will construct linear mixed models to combine dir-
ect and indirect evidence. First introduced by Lumley
[12], linear mixed models can be used to estimate the
effects of an indirect comparison with two or more link-
ing treatments (paths). For example, to pool the indirect
evidence between treatment A and treatment B, we can
combine estimates from treatment A to treatment C,
treatment B to treatment C, treatment A to treatment D,
and treatment B to treatment D. Another advantage of
linear mixed models is it can evaluate the agreement of
indirect comparisons through different linking treat-
ments, also called ‘incoherence’, and incorporate the in-
coherence in the calculation of confidence interval of
the pooled estimate. If there is direct evidence, linear
mixed models also allow us to pool direct and indirect
evidence and get more efficient estimate. R statistical
software V. 2.15.1 will be used to fit generalized linear
mixed models.
Dealing with missing data
It is likely that some eligible RCTs will not report all
relevant data such as the standard deviation or other im-
portant variability measures [13]. In order to include
these studies in the analysis we will try first to calculate
them through algebraic manipulation of the available in-
formation such as confidence intervals, p or t values. If
that was not possible, we will attempt to contact study
authors for these data. If that approach also failed we
will borrow these measures from other similar studies as
Furukawa et al. suggested. When assumptions are made
in estimating these measures, such assumptions will be
tested in sensitivity analysis [14].
Subgroup analysis
To investigate potential heterogeneity across studies, we
will conduct subgroup analysis based on class of medi-
cine, quality of evidence (low and unclear risk of bias vs
high risk of bias), oral versus topical agents, HbA1c level,
duration of diabetes, and patients’ age. Random effects
Figure 3 Formula for standard error calculation.
Figure 2 Study selection process.
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ference between subgroups and test for statistical signifi-
cant interactions among subgroups.
Sensitivity analysis
We will conduct sensitivity analysis to assess the effects
of individual studies on the combined estimates and de-
termine whether certain studies dominate the pooled
event (particularly if these studies were at high risk of
bias). Any imputations made for measures of dispersion
(that is, standard deviation) of the difference in pain out-
come will be tested in sensitivity analysis. If correlation
coefficients are needed to estimate standard deviations,
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borderline eligibility status for any reason, analysis will be
conducted with and without such studies. Finally, a major
sensitivity analysis would be to determine whether Bayesian
analysis results are different from the Frequentist method
ones. Robustness of analysis (consistency throughout sen-
sitivity analyses and assumptions) would increase our con-
fidence in the comparative effectiveness analysis.
We also plan to use the Bayesian Markov Chain Monte
Carlo method to combine direct and indirect evidence
and fit the model in WinBUGS V. 1.4.3 [15,16]. This
method allows for the pooling of indirect and direct com-
parisons of effect between the different classes of therapy
for diabetic neuropathy, while preserving within-trial
randomization, and allowing comparisons of agents not
addressed within any of the individual trials [15,16]. A
random-effects model will be fitted due to potential for
heterogeneity among included trials. The posterior distri-
bution of all parameters will be estimated using non-
informative priors, in order for results to be represented
solely by the included data. Results will be based from
100,000 iterations, after a 50,000-iteration burn-in. Incon-
sistency will be evaluated by comparing the estimates
from direct comparisons and those from the indirect com-
parisons for the magnitude and direction of effect. Appro-
priateness of model fit will be evaluated using the residual
deviance, where good model fit is represented by the re-
sidual deviance value approximating the number of un-
constrained data points [17]. The Bayesian Markov Chain
Monte Carlo method will provide us an alternative statis-
tical method to validate our results.
We will use the I2 statistic and Cochran’s Q test to as-
sess heterogeneity across studies. We will explore het-
erogeneity for potential intraclass differences.
Finally, publication bias and small study effect will be
assessed, whenever possible, using the Egger regression
asymmetry test and the Begg adjusted rank correlation
test [18,19]. All statistical analyses, except generalized lin-
ear mixed models, and the Bayesian Markov Chain Monte
Carlo method, will be conducted using STATAV. 12.0.
Reporting
The study will be reported in accordance with the recom-
mendations set forth by the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) work
groups [20]. We will present network graphs depicting
the effect size for direct, indirect and combined analyses
highlighting the quality and risk of bias in each network
loop.
Discussion
This network meta-analysis aims to synthesize available
direct and indirect evidence of effectiveness of analgesics
in the treatment of painful diabetic neuropathy. Weexpect to use evidence of inconsistency between direct
and indirect comparisons to identify publication bias
affecting the literature on head-to-head comparisons.
The network approach will offer the opportunity to gen-
erate a ranking based on efficacy. This, along with
known side effects, costs, and administration burdens
will enable patients and clinicians to make choices that
best reflect this evidence, their context, and the
informed preferences of patients with painful diabetic
neuropathy.
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